“The data are in, and it is clear that . . .a[n] experiment has failed: despite decades of research and billions of dollars invested, not a single mechanistically novel drug has reached the psychiatric market in more than 30 years.”… Continue Reading
In 2008, the FDA put out the following: “For Immediate Release: FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs.” It said: The U.S. Food and Drug Administration today exercised its new authority . . .to require manufacturers of… Continue Reading
It was indisputably bad news for the makers of the new, second-generation (or atypical) antipsychotics–a literal black mark on their name. It was April, 2005, and the FDA issued an advisory that would strike fear into the hearts of any elderly… Continue Reading
With the roll-out of Clozaril, in 1989, with its promise to treat recalcitrant schizophrenics, the era of the second-generation, or ‘atypical,’ antipsychotics, was born. And there is much the atypicals offer over the first-generation antipsychotics, including freedom from fear from the… Continue Reading
With the release of Zyprexa, a second-generation antipsychotic, Eli Lilly was certain it had hit pay dirt. The second-generation antipsychotics, known as the atypical antipsychotics, or atypicals, had an improved side effect profile over the older antipsychotics, and the original… Continue Reading
Once upon a time, if you were diagnosed with bipolar disorder, you were treated with lithium. And, once upon a time, it worked. According to the Report of the Surgeon General, “Success rates of 80 to 90 percent were once… Continue Reading
